Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Leximor Plus Susp. is a combination laxative developed and marketed by Ritz Pharma for the treatment of constipation. It typically contains a triple-action formulation consisting of liquid paraffin, magnesium hydroxide, and sodium picosulfate. Liquid paraffin acts as a lubricant laxative that softens the stool and coats the intestinal wall to facilitate passage. Magnesium hydroxide serves as an osmotic laxative, drawing water into the intestinal lumen to increase pressure and stimulate peristalsis. Sodium picosulfate is a stimulant laxative that is hydrolyzed by colonic bacteria into its active form, which directly stimulates the mucosa of the large intestine to increase motility. This combination is designed to provide comprehensive relief for acute and chronic constipation by addressing stool consistency, intestinal lubrication, and bowel movement frequency.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on liquid paraffin + magnesium hydroxide + sodium picosulfate.